Advertisement

Brains for Dementia Research: The Importance of Cohorts in Brain Banking

  • Paul T. FrancisEmail author
  • Gillian M. Hayes
  • Helen Costello
  • David R. Whitfield
Perspective
  • 40 Downloads

Background: The Historical Importance of Studies of Human Brain in Dementia Research

The collection of brain and related tissue has a long history [1]. In terms of dementia, a more systematic examination of the relationship between brain pathology and clinical symptoms can be traced to Alois Alzheimer’s group in Munich in the early 1900s [2]. The use of human brain tissue is essential to increase our understanding of dementia as it gives us the gold standard of disease pathogenesis and clues as to the molecular mechanisms that underpin the various diseases and conditions. From such human studies, experimental models can be interrogated against this standard and new treatment strategies can be discovered for these socially and economically devastating conditions.

Following reporting of the index case, it was not until the 1960s that more detailed neuropathological investigations of the brain in relation to dementia began. These studies were accompanied by efforts to introduce...

Notes

Acknowledgements

This perspective article was supported by a grant from the Alzheimer’s Society and Alzheimer’s Research UK. We thank the Brains for Dementia Research participants, donors, and their families.

References

  1. 1.
    Overy C, Tansey EM (EDs). The Development of Brain Banks in the UK c.1970–c.2010. Welcome Witnesses to Contemporary Medicine 2015, 53: 2018.Google Scholar
  2. 2.
    Bick KL, Pepeu G (EDs). The Early Story of Alzheimer’s Disease. Padova, Italy: Liviana Press, 1987.Google Scholar
  3. 3.
    Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976, 99: 459–496.CrossRefGoogle Scholar
  4. 4.
    Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, et al. Neurochemical studies of early-onset Alzheimer’s disease. Possible influence on treatment. N Engl J Med 1985, 313: 7–11.Google Scholar
  5. 5.
    Clarke NA, Francis PT. Cholinergic and glutamatergic drugs in Alzheimer’s disease therapy. Expert Rev Neurother 2005, 5: 671–682.CrossRefGoogle Scholar
  6. 6.
    Glenner GG, Wong CW. Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120: 885–890.CrossRefGoogle Scholar
  7. 7.
    Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule associated protein tau. Proc Natl Acad Sci U S A 1988, 85: 4051–4055.CrossRefGoogle Scholar
  8. 8.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004, 55: 306–319.CrossRefGoogle Scholar
  9. 9.
    Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372: 216–223.CrossRefGoogle Scholar
  10. 10.
    Yan XX, Ma C, Bao AM, Wang XM, Gai WP. Brain banking as a cornerstone of neuroscience in China. Lancet Neurol 2015, 14: 136.CrossRefGoogle Scholar
  11. 11.
    Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement 2018, 14: 483–491.CrossRefGoogle Scholar
  12. 12.
    The Lancet Neurology. Brain banking: more effective strategies needed. Lancet Neurol 2013, 12: 1035.CrossRefGoogle Scholar
  13. 13.
    Ince PG, Minett T, Forster G, Brayne C, Wharton SB, Medical Research Council Cognitive Function and Ageing Neuropathology Study. Microinfarcts in an older population-representative brain donor cohort (MRC CFAS): Prevalence, relation to dementia and mobility, and implications for the evaluation of cerebral Small Vessel Disease. Neuropathol Appl Neurobiol 2017, 43: 409–418.CrossRefGoogle Scholar
  14. 14.
    Samarasekera N, Al-Shahi Salman R, Huitinga I, Klioueva N, McLean CA, Kretzschmar H, et al. Brain banking for neurological disorders. Lancet Neurol 2013, 12: 1096–1105.CrossRefGoogle Scholar
  15. 15.
    Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, et al. Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008, 18: 484–496.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012, 123: 1–11.CrossRefGoogle Scholar
  17. 17.
    McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017, 89: 88–100.CrossRefGoogle Scholar
  18. 18.
    Skrobot OA, Attems J, Esiri M, Hortobagyi T, Ironside JW, Kalaria RN, et al. Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. Brain 2016, 139: 2957–2969.CrossRefGoogle Scholar
  19. 19.
    Patel T, Brookes KJ, Turton J, Chaudhury S, Guetta-Baranes T, Guerreiro R, et al. Whole-exome sequencing of the BDR cohort: evidence to support the role of the PILRA gene in Alzheimer’s disease. Neuropathol Appl Neurobiol 2017.  https://doi.org/10.1111/nan.12452.CrossRefGoogle Scholar
  20. 20.
    Rogers SL, Friedhoff LT. The efficacy and safety of donezepil in patients with Alzheimer’s disease: results of a US multicentre randomized, double-blind, placebo-controlled trial. Dementia 1996, 7: 293–303.PubMedGoogle Scholar
  21. 21.
    Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999, 66: 137–147.CrossRefGoogle Scholar
  22. 22.
    Francis PT, Ramirez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer’s disease. Neuropharmacology 2010, 59: 221–229.CrossRefGoogle Scholar
  23. 23.
    Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30: 572–580.CrossRefGoogle Scholar
  24. 24.
    Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science 2002, 298: 789–791.CrossRefGoogle Scholar
  25. 25.
    Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011, 32: 1207–1218.CrossRefGoogle Scholar
  26. 26.
    Vallortigara J, Whitfield D, Quelch W, Alghamdi A, Howlett D, Hortobagyi T, et al. Decreased levels of VAMP2 and monomeric alpha-synuclein correlate with duration of dementia. J Alzheimers Dis 2016, 50: 101–110.CrossRefGoogle Scholar
  27. 27.
    Baek JH, Whitfield D, Howlett D, Francis P, Bereczki E, Ballard C, et al. Unfolded protein response is activated in Lewy body dementias. Neuropathol Appl Neurobiol 2016, 42: 352–365.CrossRefGoogle Scholar
  28. 28.
    Whitfield DR, Vallortigara J, Alghamdi A, Hortobgyi T, Ballard C, Thomas AJ, et al. Depression and synaptic zinc regulation in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia. Am J Geriatr Psychiatry 2015, 23: 141–148.CrossRefGoogle Scholar
  29. 29.
    Alghamdi A, Vallortigara J, Howlett DR, Broadstock M, Hortobagyi T, Ballard C, et al. Reduction of RPT6/S8 (a Proteasome Component) and proteasome activity in the cortex is associated with cognitive impairment in Lewy body dementia. J Alzheimers Dis 2017, 57: 373–386.CrossRefGoogle Scholar
  30. 30.
    Bereczki E, Francis PT, Howlett D, Pereira JB, Hoglund K, Bogstedt A, et al. Synaptic proteins predict cognitive decline in Alzheimer’s disease and Lewy body dementia. Alzheimers Dement 2016, 12: 1149–1158.CrossRefGoogle Scholar
  31. 31.
    Bereczki E, Branca RM, Francis PT, Pereira JB, Baek JH, Hortobagyi T, et al. Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain 2018, 141: 582–595.CrossRefGoogle Scholar
  32. 32.
    Datta A, Chai YL, Tan JM, Lee JH, Francis PT, Chen CP, et al. An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. Mol Brain 2017, 10: 36.CrossRefGoogle Scholar
  33. 33.
    Xing H, Lim YA, Chong JR, Lee JH, Aarsland D, Ballard CG, et al. Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with beta-amyloid burden and synaptic deficits in Lewy body dementias. Mol Brain 2016, 9: 84.CrossRefGoogle Scholar
  34. 34.
    Ferrero H, Larrayoz IM, Martisova E, Solas M, Howlett DR, Francis PT, et al. Increased levels of brain adrenomedullin in the neuropathology of Alzheimer’s disease. Mol Neurobiol 2018, 55: 5177–5183.CrossRefGoogle Scholar
  35. 35.
    Kirvell SL, Esiri MM, Francis PT. Down regulation of vesicular glutamate transporters precede cell loss and pathology in Alzheimer’s disease. J Neurochem 2006, 98: 939–950.CrossRefGoogle Scholar
  36. 36.
    Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory - comprehensive assessment of psychopathology in dementia. Neurology 1994, 44: 2308–2314.CrossRefGoogle Scholar
  37. 37.
    Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortobagyi T, Johnson M, et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer’s disease: association with cognitive impairment. Neurobiol Aging 2014, 35: 2836–2844.CrossRefGoogle Scholar
  38. 38.
    Vallortigara J, Rangarajan S, Whitfield D, Alghamdi A, Howlett D, Hortobagyi T, et al. Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. F1000Res 2014, 3: 108.CrossRefGoogle Scholar
  39. 39.
    Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, et al. Imaging synaptic density in the living human brain. Sci Transl Med 2016, 8: 348ra396.CrossRefGoogle Scholar
  40. 40.
    Colom-Cadena M, Pegueroles J, Herrmann AG, Henstridge CM, Munoz L, Querol-Vilaseca M, et al. Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies. Brain 2017, 140: 3204–3214.CrossRefGoogle Scholar
  41. 41.
    Hannon E, Lunnon K, Schalkwyk L, Mill J. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics 2015, 10: 1024–1032.CrossRefGoogle Scholar
  42. 42.
    Dammer EB, Duong DM, Diner I, Gearing M, Feng Y, Lah JJ, et al. Neuron enriched nuclear proteome isolated from human brain. J Proteome Res 2013, 12: 3193–3206.CrossRefGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS 2019

Authors and Affiliations

  • Paul T. Francis
    • 1
    Email author
  • Gillian M. Hayes
    • 1
  • Helen Costello
    • 1
  • David R. Whitfield
    • 1
  1. 1.Wolfson Centre for Age-Related DiseasesKing’s College LondonLondonUK

Personalised recommendations